HC Wainwright Cuts Earnings Estimates for X4 Pharmaceuticals

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) – Investment analysts at HC Wainwright lowered their FY2028 earnings per share (EPS) estimates for X4 Pharmaceuticals in a note issued to investors on Thursday, March 27th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings per share of $0.00 for the year, down from their prior estimate of $0.02. HC Wainwright currently has a “Buy” rating and a $1.50 target price on the stock. The consensus estimate for X4 Pharmaceuticals’ current full-year earnings is ($0.68) per share. HC Wainwright also issued estimates for X4 Pharmaceuticals’ FY2029 earnings at $0.15 EPS.

Separately, Cantor Fitzgerald reiterated an “overweight” rating and issued a $3.00 price objective on shares of X4 Pharmaceuticals in a research note on Wednesday.

X4 Pharmaceuticals Trading Down 7.8 %

NASDAQ XFOR opened at $0.25 on Friday. The company has a current ratio of 4.89, a quick ratio of 4.80 and a debt-to-equity ratio of 1.26. X4 Pharmaceuticals has a 12 month low of $0.24 and a 12 month high of $1.60. The business’s 50-day moving average price is $0.43 and its two-hundred day moving average price is $0.52. The firm has a market capitalization of $43.42 million, a PE ratio of -2.78 and a beta of 0.39.

X4 Pharmaceuticals (NASDAQ:XFOR) last issued its quarterly earnings results on Tuesday, March 25th. The company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.03). The firm had revenue of $1.43 million for the quarter, compared to the consensus estimate of $1.07 million.

Hedge Funds Weigh In On X4 Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the stock. State Street Corp lifted its stake in shares of X4 Pharmaceuticals by 6.8% in the 3rd quarter. State Street Corp now owns 2,952,895 shares of the company’s stock valued at $1,976,000 after acquiring an additional 189,105 shares during the last quarter. Verition Fund Management LLC bought a new stake in X4 Pharmaceuticals in the 3rd quarter worth $30,000. XTX Topco Ltd increased its position in shares of X4 Pharmaceuticals by 41.7% in the third quarter. XTX Topco Ltd now owns 157,642 shares of the company’s stock valued at $106,000 after acquiring an additional 46,397 shares during the period. SG Americas Securities LLC boosted its holdings in shares of X4 Pharmaceuticals by 233.0% during the fourth quarter. SG Americas Securities LLC now owns 183,152 shares of the company’s stock worth $134,000 after purchasing an additional 128,148 shares during the period. Finally, Atria Wealth Solutions Inc. purchased a new position in X4 Pharmaceuticals during the 4th quarter valued at about $44,000. Hedge funds and other institutional investors own 72.03% of the company’s stock.

Insider Transactions at X4 Pharmaceuticals

In other X4 Pharmaceuticals news, CFO Adam S. Mostafa sold 74,773 shares of the business’s stock in a transaction dated Friday, January 24th. The shares were sold at an average price of $0.45, for a total value of $33,647.85. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Paula Ragan sold 76,473 shares of the company’s stock in a transaction dated Friday, January 24th. The shares were sold at an average price of $0.45, for a total transaction of $34,412.85. Following the sale, the chief executive officer now directly owns 1,087,386 shares in the company, valued at approximately $489,323.70. This trade represents a 6.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 202,663 shares of company stock worth $91,198 in the last quarter. 1.62% of the stock is currently owned by corporate insiders.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.